Sapropterin Dipharma Den europeiske union - norsk - EMA (European Medicines Agency)

sapropterin dipharma

dipharma arzneimittel gmbh - sapropterin dihydrochloride - phenylketonurias - andre alimentary tract and metabolism products, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Heparin Panpharma 5000 IE/ ml Norge - norsk - Statens legemiddelverk

heparin panpharma 5000 ie/ ml

panpharma (1) - heparinnatrium - injeksjonsvæske, oppløsning - 5000 ie/ ml

Nitisinone Dipharma 5 mg Norge - norsk - Statens legemiddelverk

nitisinone dipharma 5 mg

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 5 mg

Nitisinone Dipharma 10 mg Norge - norsk - Statens legemiddelverk

nitisinone dipharma 10 mg

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 10 mg

Nitisinone Dipharma 2 mg Norge - norsk - Statens legemiddelverk

nitisinone dipharma 2 mg

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 2 mg

Nitisinone Dipharma 20 mg Norge - norsk - Statens legemiddelverk

nitisinone dipharma 20 mg

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 20 mg

Navelbine 20 mg Norge - norsk - Statens legemiddelverk

navelbine 20 mg

pierre fabre pharma norden ab - vinorelbintartrat - kapsel, myk - 20 mg

Navelbine 30 mg Norge - norsk - Statens legemiddelverk

navelbine 30 mg

pierre fabre pharma norden ab - vinorelbintartrat - kapsel, myk - 30 mg

Navelbine 10 mg/ ml Norge - norsk - Statens legemiddelverk

navelbine 10 mg/ ml

pierre fabre pharma norden ab - vinorelbintartrat - konsentrat til infusjonsvæske, oppløsning - 10 mg/ ml

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Den europeiske union - norsk - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.